AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Guided Therapeutics, Inc.

$0.25 -$0.29 (-53.70%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0.25
Day Range
$0.19$0.25
Year Range
$0.15$0.54
Market Cap
24.13M
AVG Volume
12.3K
Trailing/Forward PE
-6.25/-
PEG ratio
-2.63
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD)
0200K400K600K24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q20
26 Q10
25 Q4590K
25 Q360K
25 Q2117K
25 Q10
24 Q41K
24 Q30
24 Q20
24 Q16K
Net Income (USD)
-1.5M-1M-500K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q2-604K
26 Q1-1.01M
25 Q4-1.37M
25 Q3-742K
25 Q2-811K
25 Q1-427K
24 Q4-652K
24 Q3-654K
24 Q2-709K
24 Q1-402K
Operating Income (USD)
-800K-600K-400K-200K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q2-478K
26 Q1-519K
25 Q4-710K
25 Q3-485K
25 Q2-763K
25 Q1-414K
24 Q4-533K
24 Q3-561K
24 Q2-655K
24 Q1-359K
EBITDA (USD)
-1.5M-1M-500K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q2-454K
26 Q1-495K
25 Q4-1.01M
25 Q3-586K
25 Q2-627K
25 Q1-255K
24 Q4-494K
24 Q3-522K
24 Q2-610K
24 Q1-315K
Cash Flows (USD)
-800K-600K-400K-200K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q2-319K
26 Q1-617K
25 Q4-291K
25 Q3-279K
25 Q2-169K
25 Q1-331K
24 Q4-332K
24 Q3-473K
24 Q2-214K
24 Q1-100K
EPS (USD)
-0.01-0.01-0024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP EPS (USD) by quarter
PeriodEPS (USD)
26 Q2-0.01
26 Q1-0.01
25 Q4-0.01
25 Q3-0.01
25 Q2-0.01
25 Q1-0.01
24 Q4-0.01
24 Q3-0.01
24 Q2-0.01
24 Q1-0.01
Expenses (USD)
0500K1M1.5MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Expenses (USD) by quarter
PeriodExpenses (USD)
26 Q2480K
26 Q1519K
25 Q41.17M
25 Q3522K
25 Q2842K
25 Q1414K
24 Q4531K
24 Q3561K
24 Q2655K
24 Q1363K
Cash & Debt (USD)
01M2M3MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q212K
26 Q1369K
25 Q463K
25 Q387K
25 Q2185K
25 Q1115K
24 Q4388K
24 Q3194K
24 Q2275K
24 Q1445K
Debt ratios
-1.5-1-0.5024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Debt ratios by quarter
PeriodDebt ratios
26 Q2-1.09
26 Q1-0.89
25 Q4-1.16
25 Q3-1.19
25 Q2-1.1
25 Q1-1.01
24 Q4-0.91
24 Q3-1.24
24 Q2-1.09
24 Q1-0.59
Margins
-1000%-750%-500%-250%0%250%22 Q322 Q423 Q123 Q223 Q424 Q124 Q425 Q225 Q325 Q4
GTHP Margins by quarter
PeriodMargins
25 Q477.63%
25 Q313.33%
25 Q267.52%
24 Q4-200%
24 Q166.67%
23 Q450%
23 Q225%
23 Q159.09%
22 Q4-790%
22 Q3100%
Return on Capital
-60%-40%-20%0%20%40%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Return on Capital by quarter
PeriodReturn on Capital
26 Q210.48%
26 Q119.57%
25 Q422.74%
25 Q313.14%
25 Q214.82%
25 Q1-49.02%
24 Q413.34%
24 Q313.3%
24 Q215.19%
24 Q110.02%
Shares Outstanding
025M50M75M100M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Shares Outstanding by quarter
PeriodShares Outstanding
26 Q296.54M
26 Q188.84M
25 Q478.41M
25 Q381.69M
25 Q278.84M
25 Q168.29M
24 Q457.34M
24 Q357.04M
24 Q255.99M
24 Q154.75M
Book Value Per Share (USD)
-0.1-0.08-0.05-0.03-00.0224 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q2-0.06
26 Q1-0.06
25 Q4-0.08
25 Q3-0.07
25 Q2-0.07
25 Q10.01
24 Q4-0.09
24 Q3-0.09
24 Q2-0.08
24 Q1-0.07
Total Assets (USD)
0500K1M1.5M2M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q21.2M
26 Q11.6M
25 Q41.32M
25 Q3903K
25 Q2940K
25 Q1967K
24 Q41.38M
24 Q31.25M
24 Q21.25M
24 Q11.49M
Employee Count
0510152016201720182019202020212022202320242025
GTHP Employee Count by quarter
PeriodEmployee Count
20253
20244
20234
20226
20215
20206
20198
20189
20179
201613
PE Ratio
05101520med 11.8Aug 21Oct 21Nov 21Dec 21Jan 22Feb 22Mar 22
GTHP PE Ratio by quarter
PeriodPE Ratio
Mar 2215.07
Mar 2210.84
Mar 2211.91
Mar 2211.52
Feb 2211.69
Feb 2213.53
Feb 2213.71
Feb 2214.33
Jan 2215.28
Jan 2215.48
Jan 2213.48
Jan 2215.28
Dec 2113.03
Dec 2114.61
Dec 2113.51
Dec 2113.88
Dec 2115.05
Nov 2114.38
Nov 2114.16
Nov 213.6
Nov 213.16
Oct 213.6
Oct 213.46
Oct 213.41
Oct 213.85
Oct 213.88
Sep 213.91
Sep 213.69
Sep 213.47
Sep 213.25
Aug 213.09
Aug 213.41
Free Cash Flow Yield
-30%-20%-10%0%med -6.99%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
GTHP Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-6.24%
Sep 26-7.8%
Aug 26-6.72%
Aug 26-5.78%
Aug 26-6.5%
Aug 26-5.26%
Jul 26-5.09%
Jul 26-5.87%
Jul 26-5.45%
Jul 26-5.09%
Jul 26-5.45%
Jun 26-6.36%
Jun 26-5.26%
Jun 26-7.52%
Jun 26-7.63%
May 26-6.67%
May 26-8.48%
May 26-7.63%
May 26-6.82%
May 26-5.8%
Apr 26-6.82%
Apr 26-6.82%
Apr 26-6.26%
Apr 26-5.69%
Mar 26-6.82%
Mar 26-5.04%
Mar 26-4.82%
Mar 26-4.53%
Feb 26-3.68%
Feb 26-3.4%
Feb 26-4.25%
Feb 26-3.4%
Jan 26-2.73%
Jan 26-3.49%
Jan 26-3.49%
Jan 26-3.13%
Jan 26-2.52%
Dec 25-3.78%
Dec 25-3.89%
Dec 25-5.04%
Dec 25-5.44%
Nov 25-5.44%
Nov 25-5.44%
Nov 25-8.5%
Nov 25-6.62%
Oct 25-6.13%
Oct 25-5.91%
Oct 25-7.19%
Oct 25-5.91%
Oct 25-6.92%
Sep 25-6.9%
Sep 25-5.91%
Sep 25-6.04%
Sep 25-5.91%
Aug 25-5.92%
Aug 25-6.3%
Aug 25-6.02%
Aug 25-14.01%
Aug 25-7.91%
Jul 25-7.91%
Jul 25-7.91%
Jul 25-7.6%
Jul 25-7.43%
Jun 25-7.06%
Jun 25-8.59%
Jun 25-10.4%
Jun 25-11.87%
May 25-14.12%
May 25-14.12%
May 25-15.81%
May 25-19.52%
May 25-18.59%
Apr 25-17.9%
Apr 25-20.33%
Apr 25-19.54%
Apr 25-23.51%
Mar 25-19.69%
Mar 25-19.79%
Mar 25-19.79%
Mar 25-20.51%
Feb 25-17.58%
Feb 25-14.8%
Feb 25-16.41%
Feb 25-16.01%
Jan 25-15.14%
Jan 25-15.36%
Jan 25-14.48%
Jan 25-13.77%
Jan 25-12.31%
Dec 24-13.01%
Dec 24-15.5%
Dec 24-11.33%
Dec 24-11.51%
Nov 24-10.36%
Nov 24-10.64%
Nov 24-11.58%
Nov 24-10.29%
Nov 24-12.54%
Oct 24-11.46%
Oct 24-13.37%
Price to Sales
05000100001500020000med 180.26Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
GTHP Price to Sales by quarter
PeriodPrice to Sales
Sep 2637.13
Sep 2629.7
Aug 2634.46
Aug 2640.1
Aug 2635.64
Aug 2633.59
Jul 2634.75
Jul 2630.11
Jul 2632.43
Jul 2634.75
Jul 2632.43
Jun 2627.8
Jun 2633.59
Jun 2623.51
Jun 2623.16
May 2626.52
May 2620.85
May 2623.16
May 2620.45
May 2624.04
Apr 2620.45
Apr 2620.45
Apr 2622.29
Apr 2624.54
Mar 2691.56
Mar 26123.91
Mar 26129.52
Mar 26137.68
Feb 26169.8
Feb 26183.57
Feb 26146.86
Feb 26183.57
Jan 26228.55
Jan 26178.98
Jan 26178.98
Jan 26199.58
Jan 26247.82
Dec 25165.21
Dec 25160.62
Dec 25123.91
Dec 25114.73
Nov 25114.73
Nov 25114.73
Nov 2573.43
Nov 25167.03
Oct 25180.39
Oct 25187.07
Oct 25153.73
Oct 25187.07
Oct 25159.85
Sep 25160.35
Sep 25187.07
Sep 25183.06
Sep 25187.07
Aug 25186.74
Aug 25175.65
Aug 25183.73
Aug 259634.49
Aug 2517072.75
Jul 2517072.75
Jul 2517072.75
Jul 2517755.66
Jul 2518165.41
Jun 2519121.48
Jun 2515706.93
Jun 2512975.29
Jun 2511377.28
May 259560.74
May 259560.74
May 258536.38
May 25819.13
May 25860.09
Apr 25892.85
Apr 25786.36
Apr 25818.31
Apr 25679.88
Mar 25150.1
Mar 25149.35
Mar 25149.35
Mar 25144.1
Feb 25168.11
Feb 25199.64
Feb 25180.12
Feb 25184.63
Jan 25195.13
Jan 25192.43
Jan 25204.14
Jan 25214.65
Jan 25240.16
Dec 24227.09
Dec 24190.63
Dec 24260.8
Dec 24256.68
Nov 24285.19
Nov 24277.69
Nov 24255.17
Nov 24287.3
Nov 24235.72
Oct 24257.83
Oct 24221
EV/EBITDA
0255075100med 3.82Apr 21Sep 21Oct 21Dec 21Feb 22Mar 22May 22
GTHP EV/EBITDA by quarter
PeriodEV/EBITDA
May 2272.42
May 2263.3
Apr 2279.51
Apr 2290.65
Apr 2278.49
Apr 2282.54
Apr 2280.52
Mar 224.08
Mar 223.17
Mar 223.4
Mar 223.32
Feb 223.35
Feb 223.75
Feb 223.79
Feb 223.92
Jan 224.12
Jan 224.17
Jan 223.74
Jan 224.12
Dec 213.64
Dec 213.98
Dec 213.74
Dec 213.82
Dec 214.08
Nov 213.93
Nov 213.88
Nov 212.41
Nov 212.18
Oct 212.41
Oct 212.34
Oct 212.31
Oct 212.55
Oct 212.56
Sep 212.58
Sep 212.46
Sep 212.35
Sep 212.23
Aug 212.15
Aug 212.32
May 2116.55
May 2117.89
Apr 2118.13
Apr 2116.51
Apr 2117.89
Apr 2117.48
Price to Book
510152025med 18.03May 25May 25Jun 25Jun 25Jul 25Jul 25Aug 25
GTHP Price to Book by quarter
PeriodPrice to Book
Aug 2511.06
Aug 2519.6
Jul 2519.6
Jul 2519.6
Jul 2520.39
Jul 2520.86
Jun 2521.95
Jun 2518.03
Jun 2514.9
Jun 2513.06
May 2510.98
May 2510.98
May 259.8
Guided Therapeutics, Inc.
GTHP
Stockpicker

Video analysis: GTHP

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: GTHP

Guided Therapeutics Reaches Collaborative Agreement with Türkiye's Ministry of Health to Become Primary Screening Test for Cervical Cancer

businesswire.com · 9 Sep 2026

Guided Therapeutics Reaches Collaborative Agreement with Türkiye's Ministry of Health to Become Primary Screening Test for Cervical Cancer

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced that it has reached an agreement with the Ministry of Health to co-develop LuViva for primary screening of cervical cancer in Türkiye. The first step of the collaborative agreement is to conduct an 800 patient clinical study to optimize LuViva's AI pattern recognition algorithms for real time detection of cellular changes that occur in the earliest stages of.

Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor

gurufocus.com · 22 Jul 2026

Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor

Guided Therapeutics, Inc. (OTC: QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a payment of $80,000 from distrib

Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor

businesswire.com · 22 Jul 2026

Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a payment of $80,000 from distribution partner Hangzhou Dongye Medical Technology Company Ltd (HDMT). The payment is the fourth installment of a $700,000 purchase order the Company received from HDMT last year. The four LuViva devices are expected to ship later this year, which will bring the total number of devices shipped to ele.

Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA

gurufocus.com · 16 Jun 2026

Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection ba

Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA

businesswire.com · 16 Jun 2026

Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap a.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.